As part of our ‘Ask the expert’ series, we heard from neuroscientist and psychiatrist Dr Philip Mosley about the severe impact “behavioural addictions” can have on people with Parkinson’s.
To gain further understanding about why people with Parkinson’s can develop impulsive and compulsive behaviours, Philip contributed to a study which set up a virtual casino for people with the condition. The aim was to explore why some people who take dopaminergic medication struggle with these problems.
“If we can unravel why a problem occurs, or at least explain some of the variability,” he said, “then we can deliver more accurate and personalised information to people with Parkinson’s.” Recognising the added challenges of stigma when it comes to behaviours like gambling, binge eating or hypersexuality, Philip advocates for a “non-judgemental atmosphere” to help people talk freely about these issues.
His advice? “Don’t despair – you can recover from these problems.”
US-based writer Heather Kennedy hadn’t questioned how Parkinson’s might impact her as a woman until she realised how the condition affected menstruation – and she became aware of biased perceptions within the community.
“One thing I’ve noticed in the Parkinson’s community is how women are openly shamed for experiencing impulse control disorders to do with sex,” she said. “But when it’s men, you hear that phrase: ‘Boys will be boys’. I just think that dynamic is so wrong.”
Heather herself experienced “hyper compulsion” related to cleaning and shopping. “These drugs are powerful, and they cause major changes in us,” she said. “We need more warning about that.”
These behaviours can manifest in different ways, including “compulsive spending”, says Dr Philip Mosley.
When creating a film about Parkinson’s, UK neuroscientist and writer Jon Stamford knew he wanted to avoid making something too medical or “unfocused”.
“Patients are tired of being lectured to,” he noted. “We wanted to engage with them.” To do this, he partnered with Norwegian filmmaker Anders M Leines to create a series of short films addressing the aspects of Parkinson’s that are rarely discussed openly.
“This lack of discussion, almost a conspiracy of silence, does not serve patients well,” said Jon. “People who suffered from impulse control disorders… can realise that they are not alone, and these aspects can be treated. Openness can only be good.”
When Matt Eagles first started using a ‘dopamine agonist’ (medication which mimics dopamine in the brain), it appeared to be working well. But some 18 months later, he found himself addicted to gambling apps on his phone.
“I’d go to the bathroom just to play on fruit machines, video poker and roulette in secret,” he recalled, “losing the money that my fiancée and I had saved.”
When he admitted the situation to his fiancée, the pair realised he must have been suffering from an impulse control disorder. After seeing a specialist and being weaned off the medication, Matt experienced fewer impulses to gamble. “It was such a relief,” he said.
“The drugs really did help with mobility, so coming off them has meant that my Parkinson’s is worse,” he added. “But it’s a consequence that I’ve learned to live with. The medication was literally ruining my life.”
To learn more about how impulsive and compulsive behaviours can impact people living with Parkinson’s, tune into our upcoming podcast episode on the topic – which will launch on 24 February.
Dopamine agonists for Parkinson’s: a simple introduction
Find out more about the Parkinson’s medication
1 day ago
Study suggests why neurons die in Parkinson’s disease
Researchers at the University of Córdoba, Spain, have discovered how a certain protein may be linked to death of dopamine-producing neurons associated with Parkinson’s. Using animal models of the condition to conduct their study, the team focused on the protein DJ-1 – whose link to Parkinson’s has previously been established, though its exact function was uncertain. The researchers compared neurons in the brains of mice that possessed the gene expressing DJ-1 with those that did not. The findings revealed that dysfunction or absence of the gene expressing the DJ-1 protein could trigger the ‘cell cycle’ (the process by which cells divide), which should not occur under normal conditions. Because neurons lack the capacity to divide, this causes them die – leading to the onset of symptoms linked with Parkinson’s. It is hoped that uncovering these details about the relationship between DJ-1’s absence and Parkinson’s may lead to the development of…
Researchers have finally identified brain cells linked to Parkinson’s disease
For decades, scientists have known that Parkinson’s is associated with the death of dopamine-producing cells in the brain. Now, researchers from the Broad Institute of MIT and Harvard, US, have discovered the specific subtype of brain cells that die in Parkinson’s disease. Using a technique called single-cell RNA signalling, which enables the individual analysis of cells within a tissue for activity and protein production, researchers identified 10 subtypes of dopamine-producing cells within the donated brains of people who died from causes unrelated to Parkinson’s. The team carried out the same investigation on people who had died with Parkinson’s or a condition with similar symptoms called Lewy body dementia. They discovered that only one subtype of the cells had reduced in number – which suggests many of these cells had died while the people were living. It is hoped that the findings could lead to better understanding of Parkinson’s causes and…
Tiny DBS implant shows potential to advance Parkinson’s disease treatment
In an innovative trial by North Bristol NHS Trust, UK, surgeons have succeeded in implanting a tiny deep brain stimulation (DBS) device into a person’s skull. Their aim? To address symptoms of Parkinson’s. Designed with a tiny battery system that is inserted into the skull, the DBS device delivers electric impulses to targeted areas of the brain through electric probes. In doing so, it works to address abnormal brain cell activity associated with Parkinson’s – and may help to ease symptoms. One of around 25 patients selected for the year-long trial has described the device’s impact as “amazing”. Commenting on the results of the trial so far, consultant neurologist Dr Alan Whone of North Bristol NHS Trust said: “We are hopeful that if these findings hold up, we will have a significant technical advance by which to improve Parkinson’s care across the world.”